Share on LinkedInShare on LinkedIn

ARTICLE · 30 JANUARY 2025

Correction And Interpretation Of Errors In A Patent At The UPC

In a recent decision, the UPC Court of Appeal ruled on the correction of errors in a patent by interpretation. This case, concerning Alexion Pharmaceuticals' patent (EP3167888), underscores the importance of precise drafting and consistency in arguments used during patent litigation.

United KingdomIntellectual Property

In a recent decision, the UPC Court of Appeal ruled on the correction of errors in a patent by interpretation. This case, concerning Alexion Pharmaceuticals' patent (EP3167888), underscores the importance of precise drafting and consistency in arguments used during patent litigation.

Background

EP'888 was granted in May 2024 after an EPO ex parte appeal, containing two claims designed to cover the antibody eculizumab, marketed as Soliris®:

  1. An antibody that binds C5 comprising a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4.
  2. A pharmaceutical composition comprising the antibody of claim 1.

However, due to an error in SEQ ID NO: 4, eculizumab was not directly covered by the claims.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from